Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging
Recruitment status was: Recruiting
Whole body MRI with diffusion weighted imaging is a useful imaging tool
- staging and diagnosis
- therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).
|Study Design:||Observational Model: Case-Only
Time Perspective: Prospective
|Official Title:||Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI: What is the Added Value of Diffusion Weighted Imaging in Diagnosis and Follow-up|
- Validation [ Time Frame: 2 years ]Validation of whole body MRI diffusion-weighted imaging in multiple myeloma at 3 Tesla MRI: correlation of the new MRI imaging technique (diffusion weighted imaging)to standard validated imaging technique (Computer Tomography and Magnetic Resonance Imaging)
- Therapy assessment [ Time Frame: 4 years ]
Whole body MRI with Diffusion weighted imaging is useful for treatment monitoring in multiple myeloma patients during and after therapy.
Measurement of apparent diffusion coefficient (ADC) and comparison of ADC before, during and after therapy. Correlation of ADC with clinical findings and standard MRI findings.
- outcome [ Time Frame: 5 years ]correlation between early treatment response and outcome of the patient by measuring apparent diffusion coefficient
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||September 2014|
|Estimated Primary Completion Date:||March 2013 (Final data collection date for primary outcome measure)|
|Indolent myeloma patient|
|Symptomatic Myeloma patient|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01780766
|University Hospitals Leuven|
|Principal Investigator:||Steven Pans, MD||Universitaire Ziekenhuizen Leuven|